Protalix BioTherapeutics (PLX) EBT (2010 - 2026)
Protalix BioTherapeutics' quarterly EBT came in at $21.1 million in Q1 2026, up 666.48% year-on-year from $2.8 million in Q1 2025, and up 664.21% quarter-over-quarter from -$3.7 million in Q4 2025.
Protalix BioTherapeutics has reported EBT for 17 years, with the latest figure at $21.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 666.48% year-over-year to $21.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.3 million (up 109.15% YoY), and the FY2025 full-year result was -$4.6 million, down 152.62% from the prior year.
- EBT for Q1 2026 stood at $21.1 million, up from -$3.7 million in the prior quarter.
- The five-year high for EBT was $21.1 million in Q1 2026, with the low at -$22.1 million in Q4 2023.
- Average EBT over 5 years is $223882.4, with a median of -$2.3 million recorded in 2022.
- Year-over-year, EBT tumbled 587.01% in 2023 and jumped 666.48% in 2026.
- Tracing PLX's EBT over 5 years: stood at -$3.2 million in 2022, then plunged by 587.01% to -$22.1 million in 2023, then soared by 153.8% to $11.9 million in 2024, then plunged by 131.58% to -$3.7 million in 2025, then surged by 664.21% to $21.1 million in 2026.
- The last three EBT figures came in at $21.1 million (Q1 2026), -$3.7 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 21.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.14 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 661,000.00 |
| Mar 31, 2025 | -3.73 Mn |
| Dec 31, 2024 | 11.86 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | -2.27 Mn |
| Mar 31, 2024 | -4.73 Mn |
| Dec 31, 2023 | -22.05 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Jun 30, 2023 | 19.65 Mn |
| Mar 31, 2023 | -2.94 Mn |
| Dec 31, 2022 | -3.21 Mn |
| Sep 30, 2022 | -3.57 Mn |
| Jun 30, 2022 | -5.33 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | -6.61 Mn |
| Sep 30, 2021 | -4.30 Mn |
| Jun 30, 2021 | -11.37 Mn |
| Mar 31, 2021 | -5.86 Mn |
| Dec 31, 2020 | 318,000.00 |
| Sep 30, 2020 | -4.56 Mn |
| Jun 30, 2020 | -4.19 Mn |
| Mar 31, 2020 | 1.46 Mn |
| Dec 31, 2019 | 111,000.00 |
| Sep 30, 2019 | -3.59 Mn |
| Jun 30, 2019 | -7.75 Mn |
| Mar 31, 2019 | -7.45 Mn |
| Dec 31, 2018 | -5.53 Mn |
| Sep 30, 2018 | -5.55 Mn |
| Jun 30, 2018 | -8.54 Mn |
| Mar 31, 2018 | -7.37 Mn |
| Dec 31, 2017 | -10.50 Mn |
| Sep 30, 2017 | -11.45 Mn |
| Jun 30, 2017 | -13.85 Mn |
| Mar 31, 2017 | -8.45 Mn |
| Dec 31, 2016 | -10.20 Mn |
| Sep 30, 2016 | -7.56 Mn |
| Jun 30, 2016 | -10.83 Mn |
| Mar 31, 2016 | -8.77 Mn |
| Dec 31, 2015 | -8.63 Mn |
| Sep 30, 2015 | -6.03 Mn |
| Jun 30, 2015 | -6.23 Mn |
| Mar 31, 2015 | -6.54 Mn |
| Mar 31, 2014 | -7.38 Mn |
| Dec 31, 2013 | -17.10 Mn |
| Sep 30, 2013 | -5.65 Mn |
| Jun 30, 2013 | -6.89 Mn |
| Mar 31, 2013 | -4.44 Mn |
| Dec 31, 2012 | -10.17 Mn |
| Sep 30, 2012 | -5.56 Mn |
| Jun 30, 2012 | 9.62 Mn |
| Mar 31, 2012 | -6.07 Mn |
| Dec 31, 2011 | -8.86 Mn |
| Sep 30, 2011 | -8.77 Mn |
| Jun 30, 2011 | -13.87 Mn |
| Mar 31, 2011 | -5.04 Mn |
| Dec 31, 2010 | -8.85 Mn |
| Sep 30, 2010 | -2.85 Mn |
| Jun 30, 2010 | -10.15 Mn |